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Cysteine cathepsins are a family of proteases relatively unexplored in the area of
CF lung disease. In agreement with previous work, cathepsin S (CTSS) activity
is increased in CF bronchoalveolar lavage (BAL) ﬂuid, even in the absence of
Pseudomonas aeruginosa infection, compared to healthy control BAL ﬂuid. In this
study, we investigated the hypothesis that epithelial cells contribute to the protease
burden of the CF lung by secreting CTSS. Basal expression and secretion of CTSS
were signiﬁcantly increased in CF bronchial and tracheal epithelial cell lines as well
as primary bronchial epithelial cells compared to non-CF controls in the absence
of stimulation or infection. In addition, levels of the transcription factor, IRF-1,
correlated with increased levels of its target gene, CTSS, in CF epithelial cells.
Knockdown of IRF-1 using siRNA gene silencing signiﬁcantly decreased expression
and secretion of CTSS. This novel data not only identiﬁes airway epithelial cells as
a source of CTSS in the CF lung, but also highlights a mechanism for the increased
CTSS via IRF-1. The role of CTSS in CF lung disease has long been overshadowed;
however, we believe that the IRF-1/CTSS pathway may play a functional role in
the pathogenesis of CF lung disease.
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Background: Pseudomonas aeruginosa (PA) is present in lung of cystic ﬁbrosis
(CF) patients. TLR9 is functional upon cleavage by asparagine endopeptidase (AEP)
but its role in host response to PA is unknown.
Aims: Determine the roles of TLR9 in host defense during acute lung infection by
PA.
Methods: Wild type (WT) and TLR9−/− mice were infected i.n. with 107 CFU
of a laboratory strain of PA (PAK). 24 h post-infection, we compared: mouse
survival, pro-inﬂammatory cytokine levels in broncho-alveolar lavages (BALs),
alveolar macrophages (AMs) and PMN recruitment and PA loads in lungs, cytokine
secretion by a macrophage cell line (MHS) and primary AMs.
Results: (i) TLR9−/− showed less mortality than WT mice, (ii) signiﬁcantly lower
number of AMs, PMN and bacteria were detected in BALs of TLR9−/− compared
to WT mice; (iii) decreased levels of IL-6, KC and TNFa were detected in
BALs of TLR9−/− mice; (iv) stimulation of MHS by either PAK DNA or CpG
triggered both TLR9 cleavage and cytokine secretion; (v) both an AEP inhibitor
and concanamycin B, a vacuolar H(+)-ATPase inhibitor that increases endosomal
pH, reduced CpG- and PAK DNA-induced IL-6 and TNFa secretion by MHS.
Conclusions: Signalling through TLR9 plays a role in inﬂammation induced by PA
acute lung infection. This may help to better understand the mechanisms involved
in PA-induced inﬂammation and to development of potential drugs for the treatment
of CF.
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Introduction: Fifteen to sixty percent of CF patients are colonized with As-
pergillus fumigatus (Af ) [CF-AC] and are at risk for Af infection or allergic
bronchopulmonary aspergillosis [CF-ABPA]. Although airways inﬂammation in
CF is typically characterized by neutrophilia, ABPA-associated inﬂammation is
deﬁned by eosinophilia. We hypothesized that blood and sputum eosinophils and/or
neutrophils may be primed or activated in CF-ABPA or CF-AC patients when
compared to CF patients without Af colonization or ABPA [CF].
Methods: Using ﬂow cytometry, we measured surface CD16, CD63 and CD66b on
blood and induced sputum neutrophils as well as surface CCR3 (eotaxin receptor)
on eosinophils from CF-ABPA (N= 11), CF-AC (N= 9), and CF (N= 10) patients.
We also studied the blood granulocytes from patients with celiac disease as controls.
Results: Whereas no differences were observed within the three groups of CF
patients in any activation surface markers on blood neutrophils, the levels of surface
CCR3 on blood eosinophils were increased in CF-ABPA patients compared to
CF-AC (P = 0.046). In the sputum, the levels of surface CD66b were higher on the
neutrophils from patients with CF compared to CF-AC (P = 0.03).
Conclusions: Blood neutrophil activation proﬁles are similar in CF, CF-AC and
CF-ABPA patients, while the observed increased expression of CCR3 on blood
eosinophils from patients with CF-ABPA indicates the systemic immunopathology
of this complication, complements our previously described activation of blood
basophils in CF-ABPA (JCF 2011; Suppl 1: S46). CCR3 may represent a novel
ABPA therapeutic target.
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Objectives: LPS activation of Toll like receptor 4 (TLR4) triggers internalisation
of the receptor-ligand complex which is directed towards lysosomal degradation or
endocytic recycling. The robust and uncontrolled inﬂammatory response to bacterial
infection in CF suggests a defect in this regulation. This study examined the
intracellular trafﬁcking of TLR4 in CF and non-CF airway epithelial cells following
stimulation with LPS.
Methods: We employed cell lines (16HBE14o− and CFBE41o−) and conﬁrmed
selected experiments in primary nasal epithelial cells from non-CF controls and
CF patients (F508del homozygous). Markers of the endosome, lysosome and Golgi
were assessed by Western Blot, while co-localisation of TLR4 with the lysosomal
marker LAMP1 was investigated by immunocytochemistry. Finally, TLR4 expres-
sion was determined by ﬂow cytometry.
Conclusions: All cells expressed markers of the early (EEA1) and late (Rab7b)
endosomes at basal levels. However, only CF cells displayed persistent expression
of Rab7b and the 58K Golgi protein following LPS stimulation. TLR4 co-localised
with the lysosomal marker LAMP1 in 16HBE14o− cells, suggesting that TLR4 is
targeted for lysosomal degradation in these cells. However, this co-localisation was
not observed in CFBE41o− cells, where we also found persistent expression of p65
and release of pro-inﬂammatory cytokines. Consistent with the apparent inability
of CF cells to target TLR4 towards the lysosome for degradation, we observed
persistent surface and cytoplasmic expression of this pathogen recognition receptor.
This defect may account for the prolonged cycle of chronic inﬂammation associated
with CF.
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